/RGLS

RGLS Stock - Regulus Therapeutics Inc.

Q: What is the analyst price target for RGLS?

Analyst price target information is not currently available for RGLS.

Q: What is RGLS's market cap?

Market capitalization information is not currently available for RGLS.

Healthcare|Biotechnology|NASDAQ

$8.16+0.00%

+$0.00 (+0.00%) • Jun 25

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-14.2%upside

Target: $7.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RGLS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.37

52W High$8.35

52W Low$0.83

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	$10.01M
Gross Profit	$-347,000	$-21,152,000	$-122,000	$-459,000	$9.99M
Gross Margin	N/A	N/A	N/A	N/A	99.8%
Operating Income	$-50,040,000	$-31,109,000	$-28,239,000	$-27,816,000	$-14,155,000
Net Income	$-46,358,000	$-30,037,000	$-28,323,000	$-27,808,000	$-15,730,000
Net Margin	N/A	N/A	N/A	N/A	-157.2%
EPS	$-0.82	$-1.58	$-1.86	$-3.24	$-4.50

Company Overview

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

Average Target

↓ 22.4% Downside

Now

Low

Average

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
March 27th 2025	Wells Fargo	Upgrade	Overweight	$6← $3
August 2nd 2024	Oppenheimer	Initiation	Outperform	$7
March 18th 2024	Leerink Partners	Initiation	Outperform	$6

Earnings History & Surprises

RGLS

Beat Rate

40%

Last 20 quarters

Avg Surprise

+2.6%

EPS vs Estimate

Beats / Misses

8/7

5 met exactly

Latest EPS

$-0.17

Q3 2025

EPS Surprise History

Q4 23

-11.1%

$-0.40vs$-0.36

Q1 24

0.0%

$-0.40vs$-0.40

Q2 24

-93.3%

$-0.29vs$-0.15

Q3 24

0.0%

$-0.17vs$-0.17

Q4 24

-16.7%

$-0.21vs$-0.18

Q1 25

+9.1%

$-0.20vs$-0.22

Q2 25

+48.3%

$-0.15vs$-0.29

Q3 25

+26.1%

$-0.17vs$-0.23

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Aug 14, 2025	$-0.23	$-0.17	+26.1%	✓ BEAT
Q2 2025	May 8, 2025	$-0.29	$-0.15	+48.3%	✓ BEAT
Q1 2025	Mar 13, 2025	$-0.22	$-0.20	+9.1%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.18	$-0.21	-16.7%	✗ MISS
Q3 2024	Aug 8, 2024	$-0.17	$-0.17	0.0%	= MET
Q2 2024	May 9, 2024	$-0.15	$-0.29	-93.3%	✗ MISS
Q1 2024	Mar 21, 2024	$-0.40	$-0.40	0.0%	= MET
Q4 2023	Nov 9, 2023	$-0.36	$-0.40	-11.1%	✗ MISS
Q3 2023	Aug 8, 2023	$-0.39	$-0.37	+5.1%	✓ BEAT
Q2 2023	May 11, 2023	$-0.41	$-0.42	-2.4%	✗ MISS
Q1 2023	Mar 23, 2023	$-0.49	$-0.40	+18.4%	✓ BEAT
Q4 2022	Nov 10, 2022	$-0.50	$-0.50	0.0%	= MET
Q3 2022	Aug 11, 2022	$-0.46	$-0.50	-8.7%	✗ MISS
Q2 2022	May 12, 2022	$-0.50	$-0.50	0.0%	= MET
Q1 2022	Mar 10, 2022	$-0.50	$-0.70	-40.0%	✗ MISS
Q4 2021	Nov 10, 2021	$-0.70	$-1.00	-42.9%	✗ MISS
Q3 2021	Aug 10, 2021	$-0.80	$-0.80	0.0%	= MET
Q2 2021	May 13, 2021	$-0.90	$-0.80	+11.1%	✓ BEAT
Q1 2021	Mar 9, 2021	$-1.00	$-0.30	+70.0%	✓ BEAT
Q4 2020	Nov 5, 2020	$-2.00	$-0.40	+80.0%	✓ BEAT

Frequently Asked Questions about RGLS

What is RGLS's current stock price?

Regulus Therapeutics Inc. (RGLS) is currently trading at $8.16 per share. The stock has moved +0.00% today.

What is the analyst price target for RGLS?

The average analyst price target for RGLS is $7.00, based on 1 analyst.

What sector is Regulus Therapeutics Inc. in?

Regulus Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is RGLS's market cap?

Regulus Therapeutics Inc. has a market capitalization of $0.56 billion, making it a small-cap company.

Does RGLS pay dividends?

No, Regulus Therapeutics Inc. does not currently pay a dividend to shareholders.